Immuneering (IMRX) Operating Leases: 2020-2024
Historic Operating Leases for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $4.2 million.
- Immuneering's Operating Leases fell 6.64% to $4.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.2 million, marking a year-over-year decrease of 6.64%. This contributed to the annual value of $4.2 million for FY2023, which is 6.72% down from last year.
- Immuneering's Operating Leases amounted to $4.2 million in Q3 2024, which was down 1.65% from $4.3 million recorded in Q2 2024.
- Immuneering's Operating Leases' 5-year high stood at $5.1 million during Q4 2021, with a 5-year trough of $481,965 in Q3 2021.
- In the last 3 years, Immuneering's Operating Leases had a median value of $4.5 million in 2023 and averaged $4.5 million.
- Over the last 5 years, Immuneering's Operating Leases had its largest YoY gain of 842.53% in 2022, and its largest YoY loss of 12.33% in 2022.
- Immuneering's Operating Leases (Quarterly) stood at $544,767 in 2020, then surged by 834.51% to $5.1 million in 2021, then dropped by 12.33% to $4.5 million in 2022, then fell by 6.72% to $4.2 million in 2023, then declined by 6.64% to $4.2 million in 2024.
- Its Operating Leases stands at $4.2 million for Q3 2024, versus $4.3 million for Q2 2024 and $4.4 million for Q1 2024.